NO20001458L - Behandling av opposisjonstrassforstyrrelse - Google Patents

Behandling av opposisjonstrassforstyrrelse

Info

Publication number
NO20001458L
NO20001458L NO20001458A NO20001458A NO20001458L NO 20001458 L NO20001458 L NO 20001458L NO 20001458 A NO20001458 A NO 20001458A NO 20001458 A NO20001458 A NO 20001458A NO 20001458 L NO20001458 L NO 20001458L
Authority
NO
Norway
Prior art keywords
opposition
treatment
deficit disorder
deficit
disorder
Prior art date
Application number
NO20001458A
Other languages
English (en)
Other versions
NO20001458D0 (no
Inventor
John Harrison Heiligenstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20001458L publication Critical patent/NO20001458L/no
Publication of NO20001458D0 publication Critical patent/NO20001458D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001458A 1997-09-23 2000-03-21 Behandling av opposisjonstrassforstyrrelse NO20001458D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5962997P 1997-09-23 1997-09-23
PCT/US1998/018114 WO1999015176A1 (en) 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder

Publications (2)

Publication Number Publication Date
NO20001458L true NO20001458L (no) 2000-03-21
NO20001458D0 NO20001458D0 (no) 2000-03-21

Family

ID=22024203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001458A NO20001458D0 (no) 1997-09-23 2000-03-21 Behandling av opposisjonstrassforstyrrelse

Country Status (17)

Country Link
US (1) US6028070A (no)
EP (1) EP0919236A1 (no)
JP (1) JP2001517627A (no)
KR (1) KR20010024218A (no)
CN (1) CN1146412C (no)
AU (1) AU740109B2 (no)
BR (1) BR9812357A (no)
CA (1) CA2304115A1 (no)
EA (1) EA002689B1 (no)
HU (1) HUP0003591A3 (no)
IL (1) IL134716A0 (no)
NO (1) NO20001458D0 (no)
NZ (1) NZ502810A (no)
PL (1) PL339426A1 (no)
TR (1) TR200000755T2 (no)
UA (1) UA56257C2 (no)
WO (1) WO1999015176A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010034758A (ko) 1998-04-09 2001-04-25 로렌스 티. 마이젠헬더 신경 장애의 신규 치료 방법
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
SK286669B6 (sk) 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
BR0108980A (pt) * 2000-03-07 2003-06-03 Lilly Co Eli Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6613763B2 (en) 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030203055A1 (en) * 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
KR100887982B1 (ko) * 2002-04-29 2009-03-09 알자 코포레이션 불순물 형성을 감소시키기 위한 2차 아민을 갖는 감소된포르메이트 폴리(알킬렌 옥사이드)
PL375211A1 (en) * 2002-06-17 2005-11-28 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2004075886A1 (fr) * 2003-02-14 2004-09-10 Pierre Fabre Medicament Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
EP1715856B1 (en) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
CA2779711C (en) 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
EP0537915B1 (en) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
JPH11510143A (ja) * 1995-07-24 1999-09-07 イーライ・リリー・アンド・カンパニー 注意不足／活動亢進障害の処置
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
TR200000755T2 (tr) 2000-09-21
EP0919236A1 (en) 1999-06-02
HUP0003591A3 (en) 2002-02-28
NZ502810A (en) 2002-03-01
AU9128298A (en) 1999-04-12
BR9812357A (pt) 2000-09-12
US6028070A (en) 2000-02-22
WO1999015176A1 (en) 1999-04-01
CN1270520A (zh) 2000-10-18
JP2001517627A (ja) 2001-10-09
UA56257C2 (uk) 2003-05-15
KR20010024218A (ko) 2001-03-26
EA200000349A1 (ru) 2000-10-30
NO20001458D0 (no) 2000-03-21
IL134716A0 (en) 2001-04-30
CN1146412C (zh) 2004-04-21
CA2304115A1 (en) 1999-04-01
PL339426A1 (en) 2000-12-18
HUP0003591A2 (hu) 2002-01-28
EA002689B1 (ru) 2002-08-29
AU740109B2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
NO20001458D0 (no) Behandling av opposisjonstrassforstyrrelse
NO20001479L (no) Behandling av atferdsforstyrrelse
DK0755632T3 (da) Enzymatisk behandling af kakao
DK0861081T3 (da) Anvendelse af epinastin til behandling af smerter
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DK0914103T3 (da) Behandling af hæmoglobinopati
DK0664957T4 (da) Behandling af fjerkræ
PT1032396E (pt) Esterilizacao de glucocorticoesteroides
DE69720111D1 (de) Vorläufer von Duftstoffen
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
DK0777457T3 (da) Anvendelse af glyceryltriacetat til behandling af onychomykoser
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
NO982562D0 (no) Sammensetning for behandling av smerte
DE59804303D1 (de) Herstellung von Polyenaldehyden
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO20003529D0 (no) Behandling av dyskinesi
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE59607418D1 (de) Haarbehandlungsmittel
DE69811864T2 (de) Herstellung von bandförmigen werkstücken
NO20000274D0 (no) Behandling av fluider
KR970000364U (ko) 유아용 욕조
DE59803609D1 (de) Behandlung von Kunststoffoberflächen
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application